Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084709 | 0.95 | KMT2A (0.73) | KMT2AATMMEN1KDM4EALDH1A1 | |
| Cadaverine Tartrate SCHEMBL29125517 | 0.87 | KMT2A (0.63) | KMT2AATMMEN1KDM4EALDH1A1 | |
| SCHEMBL14860179 | 0.85 | KMT2A (0.59) | KMT2AATMMEN1KDM4EALDH1A1 | |
| SCHEMBL20381852 | 0.84 | KMT2A (0.59) | KMT2AATMMEN1KDM4EALDH1A1 | |
| SCHEMBL7753404 | 0.83 | ALDH1A1 (0.62) | KMT2AATMALDH1A1MAPTLMNA | |
| SCHEMBL14859632 | 0.83 | HRH3 (0.64) | KMT2AMEN1KDM4EALDH1A1MAPT | |
| SCHEMBL28777882 | 0.83 | ALDH1A1 (0.66) | KMT2AATMMEN1KDM4EALDH1A1 | |
| SCHEMBL12222589 | 0.82 | ALDH1A1 (0.56) | KMT2AATMMEN1KDM4EALDH1A1 | |
| SCHEMBL14860115 | 0.82 | SIGMAR1 (0.61) | KMT2AATMMEN1KDM4EALDH1A1 | |
| SCHEMBL6863535 | 0.81 | KMT2A (0.68) | KMT2AATMMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4193991-A1 | OBIZIDINE FUMARATE ENTERIC-COATED PILL, PREPARATION METHOD THEREFOR AND USE THEREOF | SHENZHEN ZHENXING MEDICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-3327007-B1 | ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR | SHENZHEN ZHENXING MEDICAL TECH CO LTD (CN) | 2020-06-03 | — | — | EP | disclosed |
| EP-3327007-B1 | ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR | SHENZHEN ZHENXING MEDICAL TECH CO LTD (CN) | 2020-06-03 | — | — | EP | disclosed |
| US-10561667-B2 | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor | SHENZHEN ZHENXING MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-10561667-B2 | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor | SHENZHEN ZHENXING MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20180214456-A1 | ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR | SHENZHEN ZHENXING MEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| US-20180214456-A1 | ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR | SHENZHEN ZHENXING MEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| US-20180214456-A1 | ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR | SHENZHEN ZHENXING MEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| EP-3327007-A1 | ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR | Shenzhen Institute Of Xiangya Biomedicine (CN) | 2018-05-30 | — | — | EP | disclosed |
| EP-3327007-A1 | ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR | Shenzhen Institute Of Xiangya Biomedicine (CN) | 2018-05-30 | — | — | EP | disclosed |
| CN-105085421-B | Bit piperazine fumarate difficult to understand, hydrate, crystal formation and preparation method thereof | 深圳市湘雅生物医药研究院 | 2017-12-26 | — | — | CN | disclosed |
| CN-105085421-A | Oxetazine fumarate, hydrate, crystal form and preparation method thereof | SHENZHEN XIANGYA BIOLOG MEDICINE RES INST | 2015-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214456-A1 | ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR | FH, CYP4F11, CYP2F1 | KMT2A 3439/4885ATM 2510/4885MEN1 596/4885 |
| US-10561667-B2 | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor | FH, CYP4F11, CYP4F8 | KMT2A 3339/4885ATM 2012/4885MEN1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.